RxDoctor Payments Data

Devon Glazer, DPM

Foot & Ankle Surgery · Mission Viejo, CANPI 1235171067

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (46.8%), royalties or licence payments and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Extremity Medical at 36.2% of the total. Reporting peaked in 2023 at $61,633 and has fallen 59.0% since, to $25,287 in 2025. Among foot & ankle surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$261,795in general payments, 2019–2025

Across 322 payments — averaging $813.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Extremity Medical$95K
  • Paragon 28, Inc.$88K
  • DNE LLC$50K
  • Trice Medical, Inc.$21K
  • Tenex Health Inc.$2K
  • Zimmer Biomet$864
  • plus $6K from 41 others

What the payments were for

  • Royalty or licence$66,02425%
  • Consulting fees$122,49047%
  • Speaking & faculty fees$17,7507%
  • Travel & lodging$45,91118%
  • Food & beverage$9,6204%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$261,795 in reported general payments places this provider in the 95th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$1,978,390
Medicare patients
225
Services billed
4,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole11$15,984
Celecoxib75$1,700
Colchicine11$1,578
Ketoconazole56$1,123
Ofloxacin21$333
Gabapentin38$310
Econazole Nitrate12$309
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$243
Pregabalin17$161
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$146
Levofloxacin15$128
Meloxicam27$98
Ciprofloxacin Hcl11$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$41$15,98411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →